Published in Medical Device Business Week, February 7th, 2007
Breast cancers can be categorized as HER2 positive or HER2 negative. HER2-positive breast cancer grows more quickly and is considered more aggressive. While studies indicate that trastuzumab (Herceptin from Genentech) is effective in the treatment of HER2-positive early stage breast cancer and HER2-positive metastatic breast cancer, the drug is not effective in the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Device Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.